Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Gordana V. Vlahovic

Oncology
40 Duke Medicine Cir, 
Durham, NC 
Distinguished in Embryonal Tumor with Multilayered Rosettes
40 Duke Medicine Cir, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gordana Vlahovic is an Oncologist in Durham, North Carolina. Dr. Vlahovic is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Her clinical research consists of co-authoring 24 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

40 Duke Medicine Cir, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (Lerapolturev) in Recurrent WHO Grade IV Malignant Glioma Patients
Enrollment Status: Completed
Publish Date: July 11, 2025
Intervention Type: Biological, Drug
Study Drug: Oncolytic Polio/Rhinovirus Recombinant Vaccine
Study Phase: Phase 2
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Biological, Drug
Study Drugs: PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid, Temozolomide
Study Phase: Phase 1
Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant Glioma
Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant Glioma
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Biological
Study Drug: Recombinant nonpathogenic polio-rhinovirus chimera
Study Phase: Phase 1
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: June 08, 2023
Intervention Type: Drug, Biological
Study Drugs: Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs, 111In-labeled DCs, Temozolomide, Saline, Basiliximab
Study Phase: Phase 2
Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia
Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia
Enrollment Status: Completed
Publish Date: March 13, 2023
Intervention Type: Biological
Study Drugs: Tetanus toxoid, Therapeutic autologous dendritic cells, Therapeutic autologous lymphocytes
Study Phase: Phase 1
EGFRvIII Chimeric Antigen Receptor (CAR) Gene-modified T Cells for Patients With Newly-Diagnosed GBM During Lymphopenia
EGFRvIII Chimeric Antigen Receptor (CAR) Gene-modified T Cells for Patients With Newly-Diagnosed GBM During Lymphopenia
Enrollment Status: Terminated
Publish Date: February 17, 2023
Intervention Type: Biological
Study Phase: Phase 1
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Enrollment Status: Terminated
Publish Date: June 09, 2022
Intervention Type: Drug, Biological
Study Drugs: Temozolomide, PEP-CMV, Tetanus-Diphtheria booster, Tetanus Pre-Conditioning
Study Phase: Phase 1
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)
Enrollment Status: Completed
Publish Date: September 09, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme
REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: March 09, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors
AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors
Enrollment Status: Completed
Publish Date: March 26, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

25 Total Publications

A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial.
Journal: Nature cancer
Published: August 11, 2024
Similar Doctors
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Henry S. Friedman
Neurosurgery | Hematology | Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Henry S. Friedman
Neurosurgery | Hematology | Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Friedman is a Neurosurgery specialist and a Hematologist in Durham, North Carolina. Dr. Friedman is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. Dr. Friedman is currently accepting new patients.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. David M. Ashley
Hematology Oncology | Hematology | Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. David M. Ashley
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

20 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Ashley is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Ashley is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. Dr. Ashley is currently accepting new patients.

Mustafa Khasraw
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Mustafa Khasraw
Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Mustafa Khasraw
Oncology

Duke Health Integrated Practice Inc

40 Duke Medicine Cir, 
Durham, NC 
 (0.1 miles away)
919-684-8111
Languages Spoken:
English, Dutch
See accepted insurances
Accepting New Patients
Offers Telehealth

Mustafa Khasraw is an Oncologist in Durham, North Carolina. Dr. Khasraw is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Hip Replacement. Dr. Khasraw is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vlahovic's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile